ArticleEBioMedicine2026
Plasma metabolomic profiles and risk of hip fracture among US individuals: a nested case-control and prospective cohort study.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHip fracture is a major cause of morbidity and mortality in ageing populations. Although emerging evidence suggests a role of metabolomic profiles in osteoporosis, their association with hip fracture risk has not been well established. We aimed to investigate plasma metabolomic profiles associated with risk of hip fracture.
methodsWe conducted a nested case-control analysis (N = 1234) including 617 hip fracture cases and 617 matched controls (discovery data set) and a prospective cohort analysis including 10,031 participants (replication data set; 475 incident hip fractures) within the Nurses' Health Study and the Health Professionals Follow-Up Study. Conditional logistic regression was applied in the case-control analysis to estimate odds ratios (ORs) per 1 SD increase in metabolite levels, and Cox proportional hazards models were used in the cohort analysis. A total of 653 plasma metabolites were examined, with false discovery rate (FDR) correction applied to control for multiple testing.
findingsIn the nested-case control analysis, six metabolites related to phospholipid metabolism were consistently associated with hip fracture risk (P < 0.05), with five showing inverse associations. After FDR correction, 1-stearoyl-2-dihomo-linolenoyl-GPC, a phosphatidylcholine metabolite, remained significantly associated with lower hip fracture risk (OR 0.76, 95% CI 0.67-0.87, FDR = 0.02), and this association was replicated in the cohort analysis. At the class level, phosphatidylcholine and phosphatidylethanolamine were associated with reduced hip fracture risk (FDR = 0.01 and 0.05, respectively), with similar patterns in the replication cohort.
interpretationPlasma metabolomic profiles, particularly phospholipid metabolism pathways and phosphatidylcholine, are associated with hip fracture risk. These findings suggest altered phospholipid metabolism may contribute to the development of hip fracture and highlight potential metabolic targets for prevention.
fundingThis study was supported by NIH grants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.